SiRNA structural optimization
siRNA结构优化
基本信息
- 批准号:7132116
- 负责人:
- 金额:$ 21.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:RNA interferenceantiviral agentsbiotechnologycell growth regulationcell proliferationcell transformationchemical structure functioncooperative studygene induction /repressiongenetically modified animalshuman papillomaviruslaboratory mousemucosanucleic acid structureplasmidsribonucleosidessmall interfering RNAtechnology /technique developmenttissue /cell culturetopical drug applicationvaginavirus geneticsvirus related neoplasm /cancervirus replication
项目摘要
Human papillomaviruses (HPVs) are a major cause of anogenital and head and neck neoplasms and malignancies.
Unfortunately, no specific antiviral therapies for HPV infection or HPV-induced malignancies have been identified.
This U19 proposal is submitted as project by Alexander in a consortium proposal entitled siRNA Microbicides. The goal of this
research consortium is to develop native and chemically modified siRNAs as effective means for blocking
transmission of HIV, HSV2 and HPV. In project by Alexander, we hypothesize that chemically modified single-stranded
boranophosphate-backbone short interfering RNAs (siRNAs) are superior to native siRNAs for potent and durable
gene silencing, and that anti-HPV E6/E7 single-stranded boranophosphate-backbone siRNAs (ssBP-siRNAs) can be
used to effectively block HPV viral replication and proliferation of HPV-transformed cells. By combining chemical
modifications shown individually to increase siRNA silencing potency and duration, we will create ssBP-siRNAs,
designed for topical delivery, that block episome replication in HPV-infected cells and induce irreversible growth
arrest in HPV16-transformed cells. Anti-HPV16 ssBP-siRNAs identified by us will be tested in project 3 using novel
cell culture and transgenic mouse models of HPV infection.
Project 3 will also supply optimized ssBP-siRNAs to projects by Ramratnam and Herold to allow comparison of ssBP-siRNAs with
conventional siRNAs for targeting expression of macaque CCR5, murine focal adhesion kinase, and murine nectin-1.
To allow immediate work optimizing ssBP-siRNA delivery to vaginal mucosa, we will supply existing highly active
ssBP-siRNAs to Core B (Formulations). The vaginal mucosal uptake and activity of formulated ssBP-siRNAs will be
assessed quantitatively in project 3.
At the conclusion of this study, we will have developed anti-HPV16 E6/E7 ssBP-siRNAs as effective topical
microbicides for prevention of HPV infection and HPV-induced malignancies. We will also have created high potency
ssBP-siRNAs active against other consortium targets, and forwarded these ssBP-siRNAs for microbicidal testing in
laboratory models of viral infection.
人乳头瘤病毒(HPV)是肛门生殖器和头颈部肿瘤和恶性肿瘤的主要原因。
不幸的是,尚未确定针对HPV感染或HPV诱导的恶性肿瘤的特异性抗病毒疗法。
该U19提案由亚历山大在题为siRNA杀微生物剂的联合提案中作为项目提交。这个目标
一个研究联盟正在开发天然的和化学修饰的siRNA,作为阻断
HIV、HSV 2和HPV的传播。在亚历山大的项目中,我们假设化学修饰的单链
硼烷磷酸骨架短干扰RNA(siRNA)对于有效和持久的干扰作用优于天然siRNA(上级)。
基因沉默,并且抗HPV E6/E7单链硼磷酸骨架siRNA(ssBP-siRNA)可以被
用于有效阻断HPV病毒复制和HPV转化细胞的增殖。通过结合化学
单独显示的增加siRNA沉默效力和持续时间的修饰,我们将创建ssBP-siRNA,
设计用于局部递送,其阻断HPV感染细胞中的附加体复制并诱导不可逆生长
HPV 16转化细胞中的停滞。我们鉴定的抗HPV 16 ssBP-siRNA将在项目3中使用新的
细胞培养和HPV感染的转基因小鼠模型。
项目3还将向Ramratnam和赫罗尔德的项目提供优化的ssBP-siRNA,以允许将ssBP-siRNA与
用于靶向表达猕猴CCR 5、鼠粘着斑激酶和鼠连接蛋白-1的常规siRNA。
为了立即优化ssBP-siRNA向阴道粘膜的递送,我们将提供现有的高活性
ssBP-siRNA至核心B(制剂)。配制的ssBP-siRNA的阴道粘膜摄取和活性将被评估。
在项目3中进行了定量评估。
在这项研究的结论,我们将开发出抗HPV 16 E6/E7 ssBP-siRNA作为有效的局部
用于预防HPV感染和HPV诱导的恶性肿瘤的杀微生物剂。我们还将创造出高效能的
ssBP-siRNA对其他聚生体靶标具有活性,并将这些ssBP-siRNA转发用于微生物测试,
病毒感染的实验室模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH A ALEXANDER其他文献
KENNETH A ALEXANDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH A ALEXANDER', 18)}}的其他基金
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
6935803 - 财政年份:2004
- 资助金额:
$ 21.59万 - 项目类别:
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
6825551 - 财政年份:2004
- 资助金额:
$ 21.59万 - 项目类别:
Anti-HPV RNA Interference Using Modified RNA's
使用修饰 RNA 进行抗 HPV RNA 干扰
- 批准号:
7316076 - 财政年份:2004
- 资助金额:
$ 21.59万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6513536 - 财政年份:2000
- 资助金额:
$ 21.59万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6193673 - 财政年份:2000
- 资助金额:
$ 21.59万 - 项目类别:
COORDINATED CONTROL OF HPV TRANSCRIPTION AND REPLICATION
HPV 转录和复制的协调控制
- 批准号:
6377120 - 财政年份:2000
- 资助金额:
$ 21.59万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 21.59万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 21.59万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 21.59万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 21.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 21.59万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 21.59万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 21.59万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 21.59万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 21.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 21.59万 - 项目类别: